Prostate Cancer Clinical Trials in New York

Showing 1-20 of 352 trials

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

NCT06844383

The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate.

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)

Prostate Cancer Clinical Trials Consortium126 participantsStarted May 2026

Boston, Massachusetts, United States • New York, New York, United States

RECRUITINGPhase 1/2< 1 mile

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.

CancerColorectal CancerSolid Tumor+12 more

Parabilis Medicines, Inc.595 participantsStarted May 2023

Scottsdale, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +22 more locations

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Prostate Cancer Trials in Other Cities

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer

ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer

Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Other Conditions in New York